Electromed Joins Key Indexes Backed By Solid Growth And Stability

Electromed, Inc. (NYSE:ELMD) is one of the 11 Best Long Term Low Risk Stocks to Invest in.

Analysts maintain a Buy rating stock amid strong Q3 earnings and the company’s inclusion in the Russell 2000 and Russell 3000 Indexes.

Minnesota-based company, Electromed, Inc. (NYSE:ELMD), develops, manufactures, and markets the SmartVest System, a high‑frequency chest wall oscillation device for airway clearance therapy. Bypassing traditional equipment channels, it operates via a direct‑to‑patient and provider model. The company serves patients with pulmonary conditions such as bronchiectasis, cystic fibrosis, and neuromuscular disorders, in both home and acute care settings.

The Q3 earnings report released on May 13, 2025, indicated the 10th consecutive quarter of year-over-year revenue and net income growth. The company has achieved a year-over-year increase in revenue of 13.1% and a net income growth of 26.7%. Later, on May 27, 2025, the company announced that it will join the small-cap Russell 2000 Index and the broad-market Russell 3000 Index, effective after the close of U.S. equity markets on June 27, 2025.

Following these announcements, Freedom Capital Markets initiated coverage of the stock with a Buy rating and a price target of $29. Electromed, Inc. (NYSE:ELMD) maintains the same rating and price target at Roth Capital as well.

Now part of the Russell 2000 and Russell 3000 Indexes, the company sustains an anticipated 5-year EPS growth of 23.66% while keeping the volatility in check with a low beta of 0.39.

While we acknowledge the potential of ELMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025

Disclosure. None.